Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions

This study has been completed.
Information provided by (Responsible Party):
Alvogen Korea Identifier:
First received: August 9, 2011
Last updated: August 22, 2011
Last verified: August 2011
A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of DP-R202 tablet after oral administration in healthy male volunteers.

Condition Intervention Phase
Dietary Supplement: High fat meal
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Randomized, Single-dose, 2-sequence, 2-period Crossover Study to Investigate the Food-effect Pharmacokinetics of Sarpogrelate HCl Controlled Release Tablet in Healthy Male Subjects

Further study details as provided by Alvogen Korea:

Primary Outcome Measures:
  • Composite of Pharmacokinetics(Cmax, AUClast) [ Time Frame: 24h ]

Enrollment: 24
Study Start Date: July 2011
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: High fat meal Dietary Supplement: High fat meal
offer high fat-meal in the morning before drug intake.
Other Names:
  • Other Names:
  • DP-R202 : DP11002-3
Experimental: DP-R202
under fed condition
Dietary Supplement: High fat meal
offer high fat-meal in the morning before drug intake.
Other Names:
  • Other Names:
  • DP-R202 : DP11002-3

Detailed Description:
The number of patient is twenty-four.Patients were randomly assigned either DP-R202(Sarpogrelate HCL 300mg, qd) under fasting condition or DP-R202(Sarpogrelate HCL 300mg, qd) after eating foods.

Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 20 to 55 years of healthy volunteers

Exclusion Criteria:

  • Hypersensitivity Reaction about Sarpogrelate HCL or other antiplatelets
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01421576

Korea, Republic of
Samsung Medical Center
Seoul, Gangnam, Korea, Republic of, 135-710
Sponsors and Collaborators
Alvogen Korea
Principal Investigator: Jae Wook Ko, M.D., Ph.D Samsung Medical Center
  More Information

Responsible Party: Alvogen Korea Identifier: NCT01421576     History of Changes
Other Study ID Numbers: DP-SACL-I-002
Study First Received: August 9, 2011
Last Updated: August 22, 2011 processed this record on April 28, 2017